Literature DB >> 15677901

Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation.

Alessandro Musso1, Patrizia Dentelli, Alessandra Carlino, Luigi Chiusa, Alessandro Repici, Andreas Sturm, Claudio Fiocchi, Mario Rizzetto, Luigi Pegoraro, Carla Sategna-Guidetti, Maria Felice Brizzi.   

Abstract

Crohn's disease (CD) and ulcerative colitis (UC), the two major forms of chronic inflammatory bowel disease (IBD), are characterized by mucosal immune cell activation that is driven by a cytokine imbalance. Several cytokines involved in IBD act through the activation of the signal transducers and activators of transcription (STAT) family. We investigated the activation of STAT3 in the mucosa of CD and UC patients, and evaluated whether this event is specific for IBD patients. Using immunofluorescence and immunoblotting, total and phosphorylated STAT3 levels were assessed in biopsy specimens, isolated lamina propria mononuclear cells, and peripheral blood mononuclear cells from patients with CD, UC, other forms of intestinal inflammation, and control subjects. Immunoblotting revealed phosphorylated STAT3 in mucosal biopsy specimens from patients with CD, UC, celiac disease, and acute self-limited colitis, but not in the normal mucosa of control subjects. In IBD patients, STAT3 activation was confined to actively inflamed areas. Accordingly, activated STAT3 was detected in isolated lamina propria mononuclear cells from inflamed IBD tissues, but not in peripheral blood mononuclear cells from control subjects or IBD patients. Immunofluorescence demonstrated that the sources of activated STAT3 were macrophages and T lymphocytes, but not neutrophils. STAT3 activation also was detected in T cells infiltrating the duodenal mucosa of celiac disease patients. We conclude that STAT3 signaling occurs in both CD and UC, where it is strictly confined to areas of active inflammation and is limited to infiltrating macrophages and T cells. The occurrence of STAT3 signaling in other acute and chronic intestinal inflammatory conditions suggests that, rather than a specific feature of IBD, it represents a fundamental signaling pathway that is shared by multiple forms of gut inflammation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15677901     DOI: 10.1097/00054725-200502000-00001

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  42 in total

Review 1.  Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications.

Authors:  J Mudter; M F Neurath
Journal:  Gut       Date:  2006-09-06       Impact factor: 23.059

2.  Over-expression of CXCR4 on mesenchymal stem cells protect against experimental colitis via immunomodulatory functions in impaired tissue.

Authors:  Xingxing Liu; Dongmei Zuo; Heng Fan; Qing Tang; Zhexing Shou; Dan Cao; Zhou Zou
Journal:  J Mol Histol       Date:  2013-10-12       Impact factor: 2.611

3.  STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice.

Authors:  K Mitsuyama; S Matsumoto; S Rose-John; A Suzuki; T Hara; N Tomiyasu; K Handa; O Tsuruta; H Funabashi; J Scheller; A Toyonaga; M Sata
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

4.  The phosphatase DUSP2 controls the activity of the transcription activator STAT3 and regulates TH17 differentiation.

Authors:  Dan Lu; Liang Liu; Xin Ji; Yanan Gao; Xi Chen; Yu Liu; Yang Liu; Xuyang Zhao; Yan Li; Yunqiao Li; Yan Jin; Yu Zhang; Michael A McNutt; Yuxin Yin
Journal:  Nat Immunol       Date:  2015-10-19       Impact factor: 25.606

5.  Ex vivo immunomodulatory effect of ethanolic extract of propolis during Celiac Disease: involvement of nitric oxide pathway.

Authors:  Oussama Medjeber; Kahina Touri; Hayet Rafa; Zineb Djeraba; Mourad Belkhelfa; Amira Fatima Boutaleb; Amina Arroul-Lammali; Houda Belguendouz; Chafia Touil-Boukoffa
Journal:  Inflammopharmacology       Date:  2018-03-07       Impact factor: 4.473

6.  Oral treatment with SEW2871, a sphingosine-1-phosphate type 1 receptor agonist, ameliorates experimental colitis in interleukin-10 gene deficient mice.

Authors:  J Dong; H Wang; G Wu; J Zhao; L Zhang; L Zuo; W Zhu; J Gong; Y Li; L Gu; J Li
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

7.  Nicotine protects against DSS colitis through regulating microRNA-124 and STAT3.

Authors:  Zhen Qin; Jing-Jing Wan; Yang Sun; Tingyu Wu; Peng-Yuan Wang; Peng Du; Ding-Feng Su; Yili Yang; Xia Liu
Journal:  J Mol Med (Berl)       Date:  2016-10-05       Impact factor: 4.599

8.  The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease.

Authors:  Masayuki Fukata; Keith Breglio; Anli Chen; Arunan S Vamadevan; Tyralee Goo; David Hsu; Daisy Conduah; Ruliang Xu; Maria T Abreu
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

Review 9.  MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma.

Authors:  Xiang Li; Jing Nie; Qian Mei; Wei-Dong Han
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

10.  Gingko biloba extract (Ginaton) ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in mice via reducing IL-6/STAT3 and IL-23/IL-17.

Authors:  Yan Sun; Lian-Jie Lin; Yan Lin; Li-Xuan Sang; Min Jiang; Chang-Qing Zheng
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.